Your browser doesn't support javascript.
loading
Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugation.
Bepperling, Alexander; Richter, Gesa.
Affiliation
  • Bepperling A; Novartis TRD, Keltenring 1+3, 82041, Oberhaching, Germany. alexander.bepperling@novartis.com.
  • Richter G; Novartis TRD, Keltenring 1+3, 82041, Oberhaching, Germany.
Eur Biophys J ; 52(4-5): 393-400, 2023 Jul.
Article in En | MEDLINE | ID: mdl-37289289
ABSTRACT
Lipid nanoparticles as delivery system for mRNA have recently attracted attention to a broader audience as COVID-19 mRNA vaccines. Their low immunogenicity and capability to deliver a variety of nucleic acids renders them an interesting and complementary alternative to gene therapy vectors like AAVs. An important quality attribute of LNPs is the copy number of the encapsulated cargo molecule. This work describes how density and molecular weight distributions obtained by density contrast sedimentation velocity can be used to calculate the mRNA copy number of a degradable lipid nanoparticle formulation. The determined average copy number of 5 mRNA molecules per LNP is consistent with the previous studies using other biophysical techniques, such as single particle imaging microscopy and multi-laser cylindrical illumination confocal spectroscopy (CICS).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles / COVID-19 Limits: Humans Language: En Journal: Eur Biophys J Journal subject: BIOFISICA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles / COVID-19 Limits: Humans Language: En Journal: Eur Biophys J Journal subject: BIOFISICA Year: 2023 Document type: Article Affiliation country: